Viruses and human brain tumors: cytomegalovirus enters the fray

Cynthia Hawkins, Sidney Croul

*J Clin Invest.* 2011;121(10):3831-3833. [https://doi.org/10.1172/JCI60005.](https://doi.org/10.1172/JCI60005)

**Commentary**

Medulloblastoma is the most common malignant brain tumor in children. Overall survival rates have improved in recent years as a result of risk-stratified treatment regimens. However, medulloblastoma remains associated with substantial mortality, and survivors often experience debilitating neurological, endocrinological, and social sequelae as a result of treatment. Targeted and less toxic therapeutic strategies are therefore needed. In this issue of the *JCI*, Baryawno et al. report their findings that a large percentage of primary medulloblastomas and medulloblastoma cell lines are infected with human cytomegalovirus (HCMV) and suggest that targeting this virus could provide a new way to treat individuals with medulloblastoma.

Find the latest version:

[http://jci.me/60005/pdf](http://jci.me/60005/pdf)
Medulloblastoma is the most common malignant brain tumor in children. Overall survival rates have improved in recent years as a result of risk-stratified treatment regimens. However, medulloblastoma remains associated with substantial mortality, and survivors often experience debilitating neurologic, endocrinologic, and social sequelae as a result of treatment. Targeted and less toxic therapeutic strategies are therefore needed. In this issue of the JCI, Baryawno et al. report their findings that a large percentage of primary medulloblastomas and medulloblastoma cell lines are infected with human cytomegalovirus (HCMV) and suggest that targeting this virus could provide a new way to treat individuals with medulloblastoma.

Brain tumors account for 20% of all neoplasms in children and are the largest group of solid tumors that develop in childhood (1). Medulloblastoma is the most common malignant pediatric brain tumor, constituting 20%–25% of pediatric central nervous system neoplasms (2, 3). Its incidence is estimated at 2–6 cases per million children per year, with approximately 540 new cases diagnosed annually in the United States (2, 4). Medulloblastoma typically arises in the midline cerebellum, in the region of the mid- and inferior vermis. Current treatment includes surgery, craniospinal irradiation, and chemotherapy. Overall survival for all medulloblastoma patients is roughly 50%–60% in population-based studies (5). However, as we have gained a better understanding of clinical risk factors, the incorporation of patient stratification in larger, multi-institutional studies has resulted in improved survival. Currently, there are three major treatment strategies for medulloblastoma patients based on their clinical status. For patients younger than 3–5 years, treatments are aimed at maximizing survival while avoiding radiation (6, 7). Older patients are stratified by the extent of resection and metastatic status. Patients with metastatic disease or a less-than-optimal resection are classified as high-risk and are treated with high doses of craniospinal irradiation (36–39 Gy) and aggressive chemotherapy. Patients with totally, or near-totally, resected disease or a less-than-optimal resection are classified as standard-risk. For patients with these risk factors, the incorporation of adjuvant chemotherapy has resulted in improved survival (8, 9). Despite the improved survival, there still remains a substantial amount of mortality associated with medulloblastoma, and survivors often experience neurologic, endocrinologic, and social sequelae as a result of treatment. Thus, many researchers are seeking to develop new, more targeted and less toxic therapeutic strategies. In this issue of the JCI, Baryawno et al. describe a potential novel therapeutic strategy for medulloblastoma.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Investig. 2011;121(10):3831–3833. doi:10.1172/JCI60005.
that takes advantage of their finding that human cytomegalovirus (HCMV) is frequently expressed in such tumors (10).

**Can viruses cause brain tumors?**

Whether viruses have a causal role in brain tumor development has been hotly debated for decades (11). Epidemiologic data pointing to a potential role for viruses in the development of brain tumors include several studies reporting an increased risk of developing a childhood brain tumor in individuals whose mothers were infected with various viruses, such as those that cause chickenpox, mumps, and rubella, during pregnancy (12, 13). However, the largest area of inquiry into the possibility of an infectious etiology of brain tumors comes from studies of polyomaviruses, a genus of viruses that includes simian vacuolating virus 40 (SV40). In vitro, the T antigen encoded by many polyomaviruses readily transforms cells and induces CNS tumors, including medulloblastomas, gliomas, and choroid plexus papillomas, in a variety of animal models (14). Human studies correlating viruses and brain tumors include epidemiological studies suggesting that polyoma virus–contaminated vaccinations administered to women in the 1950s and ’60s were associated with increased risk of brain tumors in their children (15–17), and more recently, those indicating the presence of polyoma DNA and protein in human brain tumors, including the detection of polyoma JC virus in medulloblastoma (18). Despite the spate of early experiments indicating a potential role for polyomaviruses in brain tumor formation, over time it has been difficult, some would say near impossible, to move from correlation to cause in the arena of human brain tumors. Over the years, the literature has been peppered with claims and counterclaims of polyomavirus detection in human tumor specimens (18, 19), but definitive proof of polyomaviruses causing brain tumors is still not available.

**Can viruses be used to treat brain tumors?**

The controversy surrounding the potential causal role of viruses in brain tumor development has been swirling for years. More recently, however, interest in viral CNS tumor pathogenesis has yielded to the related field of viral therapy for brain tumors (20). Oncolytic viral therapy uses replication-competent viruses to selectively infect and kill cancer cells while leaving normal, non-transformed cells intact. Viruses used in this way in clinical trials for malignant glial brain tumors include herpes simplex viruses, adenoviruses, reoviruses, and Newcastle disease viruses (20). Although in trial for malignant gliomas, this strategy has not yet been evaluated for the treatment of medulloblastoma. However, preclinical data exist suggesting that measles virus might be an effective oncolytic virus in individuals with medulloblastoma (21). Studebaker et al. demonstrated that the measles virus receptor CD46...
Can the presence of virus be used to target brain tumors therapeutically?

HCMV DNA and proteins have been found in tumors of different origins, including 90%–100% of high-grade glial brain tumors (24). Unlike polyomaviruses, CMV is not considered to be oncogenic itself and has likewise not been used as an oncolytic virus. In this issue of the JCI, Baryawno et al. report their work examining the prevalence of HCMV in medulloblastomas and whether the presence of the virus can be used to target medulloblastoma therapeutically (10). Of the 37 primary medulloblastomas examined by Baryawno et al. (10), we may be able to exploit our knowledge of the presence of viruses and viral antigens in brain tumors to develop novel therapies for these devastating diseases.

Conclusion

Whether viruses are a major cause of brain tumors may never be conclusively determined. However, as shown by Baryawno et al. (10), we may be able to exploit our knowledge of the presence of viruses and viral antigens in brain tumors to develop novel therapies for these devastating diseases.

Acknowledgments

Cynthia Hawkins is funded by grants from the Canadian Institutes for Health Research (MOP115004) and the National Brain Tumor Society.

Address correspondence to: Cynthia Hawkins, Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada. Phone: 416.813.5938; Fax: 416.813.5974; E-mail: cynthia.hawkins@sickkids.ca.

2. McNeil DE, Cost TR, Clegg L, Rorke LB. Incidence and trends in pediatric malignancies medulloblas-
3. Park TS, Hoffman HJ, Hendrick EB, Humphreys RP, Becker LE. Medulloblastoma: clinical presenta-
4. Roberts RO, Lynch CF, Jones MP, Hart MN. Medul-
8. Gajjar A, et al. Risk-adapted craniospinal radio-
9. Packer RJ, et al. Phase III study of craniospinal radi-
14. Croul S, Otte J, Khalili K. Brain tumors and poly-
15. Farwell JR, Doehrmann GJ, Flannery JT. Medul-
16. Fraumeni JF Jr, Stark CR, Gold E, Lepow ML. Sim-
18. Khalili K, Kynska B, Del Valle L, Karsatos CD, Croul S. Medulloblastomas and the human neu-
22. Lun XQ, et al. Targeting human medulloblas-
toma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res. 2007; 67(18):8818–8827.
23. Yu L, et al. A single intravenous injection of oncol-
ytic picornavirus SYV-001 eliminates medulloblas-